tiprankstipranks
Advertisement
Advertisement

PHAR Stock Latest News

Pharming price target raised to $38 from $37 at Canaccord
The FlyPharming price target raised to $38 from $37 at Canaccord
20d ago
PHAR
Pharming cuts FY26 revenue view to $375M-$395M from $405M-$425M
PremiumThe Fly
Pharming cuts FY26 revenue view to $375M-$395M from $405M-$425M
24d ago
PHAR
Pharming reports Q2 EPS 2c, consensus 6c
PremiumThe Fly
Pharming reports Q2 EPS 2c, consensus 6c
24d ago
PHAR
Buy Rating Reaffirmed on Joenja’s European Expansion and Pediatric FDA Catalyst; $37 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Joenja’s European Expansion and Pediatric FDA Catalyst; $37 Price Target Maintained
2M ago
PHAR
Pharming: Profitable Core, Advancing Pipeline Underpin Buy Rating and Maintained $37 Price Target
PremiumRatings
Pharming: Profitable Core, Advancing Pipeline Underpin Buy Rating and Maintained $37 Price Target
2M ago
PHAR
Pharming Wins FDA Review for Joenja Pediatric sNDA in APDS
PremiumCompany AnnouncementsPharming Wins FDA Review for Joenja Pediatric sNDA in APDS
3M ago
6K
PHAR
Pharming Group appoints KPMG as new auditor as shareholders back full AGM agenda
Premium
Company Announcements
Pharming Group appoints KPMG as new auditor as shareholders back full AGM agenda
3M ago
6K
PHAR
Pantginis Reiterates Buy on Pharming as Joenja’s Global Expansion Advances; $37 Price Target Maintained
Premium
Ratings
Pantginis Reiterates Buy on Pharming as Joenja’s Global Expansion Advances; $37 Price Target Maintained
3M ago
PHAR
Pharming Wins EU Green Light for Joenja, First Approved Treatment for APDS
PremiumCompany Announcements
Pharming Wins EU Green Light for Joenja, First Approved Treatment for APDS
3M ago
6K
PHAR
Pharming’s Joenja granted marketing authorization by European Commission
PremiumThe Fly
Pharming’s Joenja granted marketing authorization by European Commission
3M ago
PHAR
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/8/2026
PremiumMarket News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/8/2026
4M ago
IVA
ATAI
Pharming price target lowered to $40 from $41 at Oppenheimer
PremiumThe Fly
Pharming price target lowered to $40 from $41 at Oppenheimer
4M ago
PHAR
Pharming reports Q1 EPS 1c, consensus 0c
PremiumThe FlyPharming reports Q1 EPS 1c, consensus 0c
4M ago
PHAR
Pharming sees FY26 revenue $405M-$425M, consensus $411.9M
Premium
The Fly
Pharming sees FY26 revenue $405M-$425M, consensus $411.9M
4M ago
PHAR
Pharming Posts Mixed Q1 2026 as Joenja® Growth Offsets RUCONEST® Decline and Global Label Expansion Advances
Premium
Company Announcements
Pharming Posts Mixed Q1 2026 as Joenja® Growth Offsets RUCONEST® Decline and Global Label Expansion Advances
4M ago
6K
PHAR
Pharming Group Showcases New Leniolisib Data and Expands Immunology Focus at CIS 2026
PremiumCompany Announcements
Pharming Group Showcases New Leniolisib Data and Expands Immunology Focus at CIS 2026
4M ago
6K
PHAR
Pharming Group Sets May 28, 2026 AGM With Key Governance and Capital Measures on Agenda
PremiumCompany Announcements
Pharming Group Sets May 28, 2026 AGM With Key Governance and Capital Measures on Agenda
4M ago
6K
PHAR
Pharming initiated with a Buy at Canaccord on growth potential
PremiumThe Fly
Pharming initiated with a Buy at Canaccord on growth potential
4M ago
PHAR
Pharming initiated with a Buy at Canaccord
PremiumThe Fly
Pharming initiated with a Buy at Canaccord
4M ago
PHAR
Pharming Group Files 2025 Annual Report and Form 20-F
PremiumCompany AnnouncementsPharming Group Files 2025 Annual Report and Form 20-F
5M ago
6K
PHAR
Pharming Group Wins Positive EMA Panel Backing for Joenja in Rare APDS
Premium
Company Announcements
Pharming Group Wins Positive EMA Panel Backing for Joenja in Rare APDS
5M ago
6K
PHAR
Pharming announces approval of Joenja in Japan for patients aged 4 years and old
Premium
The Fly
Pharming announces approval of Joenja in Japan for patients aged 4 years and old
5M ago
PHAR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >